Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 sept. 2015 14h45 HE | Source: Viventia Bio Inc.

Viventia Expands Leadership Team, Names Arthur P. DeCillis, M.D., as Chief Medical Officer

WINNIPEG, Manitoba, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that Arthur P. DeCillis,...
04 sept. 2015 12h10 HE | Source: Viventia Bio Inc.

Viventia Reports on Progress of Anti-Cancer Pipeline at PEGS Korea 2015

WINNIPEG, Manitoba and PHILADELPHIA, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, announced that Gregory...
16 juil. 2015 08h00 HE | Source: Viventia Bio Inc.

Viventia Recognizes Chairman Leslie Dan's 50 Years of Leadership in Healthcare

WINNIPEG, Manitoba, July 16, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today recognized Leslie L. Dan, Founder...
02 juil. 2015 12h45 HE | Source: Viventia Bio Inc.

Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer

WINNIPEG, Manitoba, July 2, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that they have begun...
23 juin 2015 08h00 HE | Source: Viventia Bio Inc.

Viventia Announces 2015 Additions to Its Board of Directors

WINNIPEG, Manitoba, June 23, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of its...
17 juin 2015 08h00 HE | Source: Viventia Bio Inc.

Viventia Presents Validating Evidence for Highly Differentiated De-immunized Payload for Oncology at 13th Empowered Antibodies Conference

- Viventia's Protein Toxin DeBouganin Shows Advantages in Uniform Killing of Diverse Cancer Cell Lines, Avoidance of Multi-Drug Resistance Affecting Small Molecule Toxins, and Efficacy against...
05 juin 2015 08h00 HE | Source: Viventia Bio Inc.

Viventia Bio Inc. Expands Leadership Team, Names Erick Lucera as Chief Financial Officer and Gregory Adams, Ph.D., Chief Product Development Officer

WINNIPEG, Manitoba, June 5, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of the...